Journal article

Bujar et al 2019 – Quality decision making in Health Technology Assessment

Background: To evaluate the quality of the decision-making processes of pharmaceutical companies during medicines development for evidence generation to support reimbursement of new medicines and the appraisal recommendation decision-making process [...]

2025-12-11T13:08:44+00:00March 4th, 2019|Tags: , |

Bujar et al 2019 – Reliability and relevance of a decision-making instrument

Introduction: The Quality of Decision-Making Orientation Scheme (QoDoS) was developed to provide organisations involved in submission, approval and reimbursement of new medicines with a tool to improve the quality [...]

2025-12-11T13:09:20+00:00January 31st, 2019|Tags: , , |

Wang et al 2018 – Building Synergy between Regulatory and HTA Agencies

Objectives: To evaluate the current practice of companies and agencies to assess the changes made in aligning regulatory and health technology assessment (HTA) stakeholders; to identify areas of commonality [...]

2025-12-11T13:11:35+00:00July 22nd, 2018|Tags: , , |

Haqaish et al 2017 – Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore

Objective: This study compares the current regulatory review process and good review practices at the Saudi Food and Drug Authority (SFDA) with those of regulatory agencies in Australia, Canada, [...]

2026-02-05T16:44:11+00:00January 1st, 2017|Tags: , |

Bujar et al 2016 – Quality of Regulatory Decision-Making Practices

Background The science of decision making is well established, although in reality it is a mixture of science and art. What is currently lacking is research into decision making [...]

2026-02-20T14:57:06+00:00December 30th, 2016|Tags: , |

Hashan et al 2016 – Saudi Arabia FDA: An Evaluation of the Registration Process and Good Review Practices in Saudi Arabia in Comparison with Australia, Canada and Singapore

Objective: This study compares the current regulatory review process and good review practices at the Saudi Food and Drug Authority (SFDA) with those of regulatory agencies in Australia, Canada, [...]

2026-02-05T16:53:37+00:00February 1st, 2016|Tags: , |

Walker et al 2015 – Universal Framework for the Benefit-Risk Assessment of Medicines

A universal framework for the evaluation of the benefit-risk assessment of medicines during development by pharmaceutical companies and in the regulatory review by regulatory authorities is considered of value, [...]

2020-07-22T10:41:37+00:00January 22nd, 2015|Tags: , |

Liu et al 2013 – Characterising Good Review Practices across APEC agencies

As a first step in the implementation of the Asia-Pacific Economic Cooperation (APEC) Best Regulatory Practice Project, the Centre for Innovation in Regulatory Science conducted a gap analysis survey [...]

2024-12-18T16:21:25+00:00December 1st, 2013|Tags: , |
Go to Top